论文信息 - Reduction of serum thymus and activation‐regulated chemokine after short‐term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis

Reduction of serum thymus and activation‐regulated chemokine after short‐term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis

OTSUKI, Kentaro KURITANI, Sachiko HIJIKI, Satoshi NOJIMA, Ichiro KATAYAMA, Mika TERAO, Shigeki INUI, Manabu FUJIMOTO Departments of Dermatology, Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Department of Obstetrics and Gynecology, Itami City Hospital, Itami, Departments of Pathology, and Regenerative Dermatology, Osaka University Graduate School of Medicine, Suita, Japan

[1] Y. Kataoka,et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016 , 2016, The Journal of dermatology.

[2] Y. Kataoka. Thymus and activation‐regulated chemokine as a clinical biomarker in atopic dermatitis , 2014, The Journal of dermatology.

[3] K. Tamaki,et al. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. , 2006, Journal of dermatological science.

[4] T. Bito,et al. Serum TARC/CCL 17 Levels as a Disease Marker of Atopic Dermatitis , 2006 .

[5] Koichiro Nakamura,et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. , 2001, The Journal of allergy and clinical immunology.